Please login to the form below

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.

At Fishawack Health (FH), we are committed to investing in the field of dermatology. In November 2021, we welcomed FIDE, an independent network of expert partners in dermatology, to inform industry specialists as to the potential impact of the latest data and how it may affect their strategic decision making. FIDE joins other Expert Partnerships at FH including IHEP, which specializes in diseases of the liver and i-ONE, which specializes in oncology and hematology. Each Expert Partnership offers unparalleled access to the latest insights from the world’s leading key opinion leaders.

FIDE’s services range from detailed, unbiased conference analysis programs to consulting and training initiatives that bridge the gap between industry’s understanding of the field and real-world clinician and patient perspectives.

We sat down with members of the FIDE Steering Committee to explore the latest key insights and trends in 5 inflammatory skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa. They examined the complexities of the space and outlined the challenges that new and innovative treatments and technologies can help address, from meeting unmet needs to improving in the provision of high standards of clinical care.

CLICK HERE TO DOWNLOAD FULL ARTICLE

18th August 2022

Share

Tags

Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

Address:
No. 3 Booths Park
Booths Hall
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom

Latest content on this profile

Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset.
Fishawack Health
Geoff Thorne joins FH as Chief Technology Officer to drive innovation for clients
The experienced executive will expand our cross-functional omnichannel, data and analytics, and technology offerings, developing effective solutions to meet our clients’ evolving needs.
Fishawack Health
Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.
Fishawack Health
How the WHO hepatitis strategy measures up in the field
With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination by 2030 and reveals his dynamic and novel colocalization method designed to meet patients where they are.
Fishawack Health
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.
Fishawack Health
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in a digital world.
Fishawack Health